Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($) $ in Millions |
12 Months Ended | 59 Months Ended | ||||
|---|---|---|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Dec. 31, 2012 |
Dec. 31, 2016 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Upfront and milestone payments received to date | $ 110.0 | $ 110.0 | ||||
| Collaboration payments achieved and received | $ 42.5 | $ 67.5 | ||||
| Revenue recognized by the Company | $ 76.9 | $ 14.7 | ||||
| Company received a reimbursement for eligible worldwide development expenses | $ 1.6 | $ 11.6 | $ 21.9 | |||
| Collaborative Arrangement Product Agreement | Evofosfamide | ||||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
| Merck KGaA's percentage share of worldwide development expenses | 70.00% | |||||
| X | ||||||||||
- Definition Collaboration payments achieved and received. No definition available.
|
| X | ||||||||||
- Definition Merck KGaA's percentage share of worldwide development expenses. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|